Prescient Therapeutics bone marrow cancer trial progresses
Melbourne biotech company Prescient Therapeutics (ASX:PTX) says a clinical trial evaluating its PTX-200 drug candidate to treat...
Melbourne biotech company Prescient Therapeutics (ASX:PTX) says a clinical trial evaluating its PTX-200 drug candidate to treat...
Prescient Therapeutics (PTX) will progress to the next dose level of its Phase 1b clinical...
The market for revolutionary CAR-T cancer treatments is expected to grow to USD 14 billion...
When JVC launched VHS videos in 1971, it started a consumer revolution that permanently altered...
Two ASX-listed ventures are among the companies now investing billions of dollars to develop an...
The burgeoning CAR T therapy industry has passed another significant milestone after the US Food...
Australian listed biotech company Prescient Therapeutics (ASX: PTX) is forging a path for other prospective...
StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each...
Several major pharmaceutical companies have cautioned they’re unable to widely use revolutionary CAR-T cancer treatments,...
There are several ASX stocks fighting cancer but only a few are addressing blood cancers....

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.